This retrospective, panel-based online physician chart review aimed to assess effectiveness of quarterly and monthly fremanezumab for reducing monthly migraine days (MMDs) and monthly headache days (MHDs) in adult migraine patients over ≤6 months.

Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP), has been approved for preventive migraine treatment in adults. Real-world effectiveness data for fremanezumab dosed quarterly and monthly are needed to fully understand the clinical benefits of treatment.

This panel-based chart review used electronic case report forms. Patient inclusion criteria were physician-diagnosed chronic migraine (CM) or episodic migraine (EM); fremanezumab treatment initiation at ≥18 years of age after FDA approval (treatment initiation, October 2, 2018–July 17, 2020); ≥1 dose of fremanezumab treatment; and ≥2 MMD assessments (1 within 30 days before treatment initiation and ≥1 after initiation).

Data from 421 clinicians and 1,003 patients (dosing: quarterly, n=381; monthly, n=622) were used. For patients receiving quarterly and monthly dosing, respectively, mean age at initiation was 39.4 and 39.8 years; 71% and 79% of patients were female. With quarterly and monthly dosing, respectively, mean baseline MMDs were 11.9 and 13.2, and baseline MHDs were 12.9 and 14.8 (both P≤0.002 for quarterly vs monthly). Both fremanezumab doses were effective for providing sustained reductions in MHDs and MMDs. Changes from baseline did not differ significantly for quarterly versus monthly dosing for MMDs at Month 1 (mean [percent] reductions: –3.9[32.8%] vs –4.9[37.1%]), Month 3 (–6.2[52.1%] vs –7.2[54.5%]), or Month 6 (–9.5[79.8%] vs –8.9[67.4%]) or for MHDs at Month 1 (–3.7[28.7%] and –5.1[34.5%]), Month 3 (–6.0[46.5%] vs –7.7[52.0%]), or Month 6 (–9.7[75.2%] vs –9.8[66.2%]).

In this real-world study, both quarterly and monthly fremanezumab resulted in clinically meaningful reductions in MMDs and MHDs over ≤6 months.